136
Participants
Start Date
June 20, 2022
Primary Completion Date
December 4, 2026
Study Completion Date
May 21, 2027
Emicizumab
The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
Észak-Pesti Centrumkórház - Honvédkórház, Budapest
CHU Farhat Hached, Sousse
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique, Rabat
University Clinical Centre of Serbia, Belgrade
Charité Universitätsklinikum Berlin, Berlin
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña
Hospital Universitario la Paz, Madrid
Hospital Regional Universitario Carlos Haya, Málaga
University of Miami Medical Center, Miami
Istanbul University Cerrahpasa Medical Faculty, Istanbul
Ege Uni Medical School, Izmir
AOU Careggi, Florence
Universitätsklinikum Bonn, Bonn
Oklahoma Children's Hospital ? Jimmy Everest Center, Oklahoma City
AOU Federico II, Napoli
Orthopaedic Institute for Children, Los Angeles
Hospital das Clinicas - UNICAMP, Campinas
Hospital das Clínicas Faculdades Médicas de Ribeirão Preto, Ribeirão Preto
Hamilton Health Sciences Corporation, Hamilton
Policlinico Univ. A. Gemelli, Rome
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitario Vall de Hebron, Barcelona
Aziza Othmana Hospital, Tunis
Gazi Universitesi Tip Fakultesi, Ankara
Akdeniz Uni School of Medicine, Antalya
St Thomas Westminster, London
Manchester University NHS Foundation Trust (MFT), Manchester
Hoffmann-La Roche
INDUSTRY